keyword
MENU ▼
Read by QxMD icon Read
search

Primary mediastinic lymphoma

keyword
https://www.readbyqxmd.com/read/28078727/second-cancer-incidence-in-primary-mediastinal-b-cell-lymphoma-treated-with-methotrexate-with-leucovorin-rescue-doxorubicin-cyclophosphamide-vincristine-prednisone-and-bleomycin-regimen-with-or-without-rituximab-and-mediastinal-radiotherapy-results-from-a-monoinstitutional
#1
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3...
January 12, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28046973/su-f-r-14-pet-based-radiomics-to-predict-outcomes-in-patients-with-hodgkin-lymphoma
#2
J Lee, M Aristophanous, M Akhtari, S Milgrom, D Bouthaina, C Pinnix, S Narang, A Rao, L Court, G Smith
PURPOSE: To identify PET-based radiomics features associated with high refractory/relapsed disease risk for Hodgkin lymphoma patients. METHODS: A total of 251 Hodgkin lymphoma patients including 19 primary refractory and 9 relapsed patients were investigated. All patients underwent an initial pre-treatment diagnostic FDG PET/CT scan. All cancerous lymph node regions (ROIs) were delineated by an experienced physician based on thresholding each volume of disease in the anatomical regions to SUV>2...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28010897/brentuximab-vedotin-for-treatment-of-non-hodgkin-lymphomas-a-systematic-review
#3
REVIEW
Garrett K Berger, Ali McBride, Stephanie Lawson, Kelsey Royball, Seongseok Yun, Kevin Gee, Irbaz Bin Riaz, Ahlam A Saleh, Soham Puvvada, Faiz Anwer
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD)...
January 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28002527/rare-thymic-malignancy-of-b-cell-origin-t-cell%C3%A3-histiocyte-rich-large-b-cell-lymphoma
#4
Ileana Octavia Petrescu, Iancu Emil Pleşea, Maria Camelia Foarfă, Simona Bondari, Cristina Elena Singer, Elena Mădălina Dumitrescu, Răzvan Cosmin Pană, Georgeta Ligia Stănescu, Mircea Ovidiu Ciobanu
AIM: T-cell÷histiocyte-rich B-cell lymphoma is a rare type of diffuse large B-cell lymphoma reported as involving primarily the thymus only by one paper in the English literature. CASE PRESENTATION: A four and a half years old boy was admitted, after a sudden onset in the middle of the night, with superior vena cava syndrome, resuscitated cardiac and respiratory arrest and severe coma with Glasgow Coma Scale rate of 3. In spite of intensive treatment, the patient repeated twice the cardiac arrest and died sixteen hours after admittance...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27936978/mature-aggressive-b-cell-lymphoma-across-age-groups-molecular-advances-and-therapeutic-implications
#5
Jonas Lange, Georg Lenz, Birgit Burkhardt
Mature B-cell lymphoma represents the most common type of Non-Hodgkin lymphoma, and different subtypes prevail at different patient ages. Areas covered: We review recent data on differences and commonalities in mature B-cell lymphoma occurring in adult and pediatric patients, with a special emphasis on molecular advances and therapeutic implications. To this end, we will discuss knowledge on diffuse large B-cell lymphoma and Burkitt lymphoma/leukemia, which are the most frequent subtypes in adult and pediatric patients, respectively, and on primary mediastinal B-cell lymphoma, which is a subtype of mature B-cell lymphoma occurring mainly in adolescents and young adults with a female predominance...
December 26, 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27935768/hypertrophic-osteoarthropathy-clinical-and-imaging-features
#6
Felix Y Yap, Matthew R Skalski, Dakshesh B Patel, Aaron J Schein, Eric A White, Anderanik Tomasian, Sulabha Masih, George R Matcuk
Hypertrophic osteoarthropathy (HOA) is a medical condition characterized by abnormal proliferation of skin and periosteal tissues involving the extremities and characterized by three clinical features: digital clubbing (also termed Hippocratic fingers), periostosis of tubular bones, and synovial effusions. HOA can be a primary entity, known as pachydermoperiostosis, or can be secondary to extraskeletal conditions, with different prognoses and management implications for each. There is a high association between secondary HOA and malignancy, especially non-small cell lung cancer...
January 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/27888880/optimizing-outcomes-in-primary-mediastinal-b-cell-lymphoma
#7
REVIEW
Pier Luigi Zinzani, Alessandro Broccoli
Primary mediastinal B-cell lymphoma is characterized by a high chance of cure, and cured patients have a long disease-free life-expectancy; however, prognosis is severe in the case of relapsed or refractory disease. The initial use of the most effective chemoimmunotherapy regimen is therefore crucial. Understanding who will benefit from postinduction radiotherapy is also of paramount importance; positron emission tomography may be a reliable guide for physicians in determining which patients will require consolidation...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27884092/a-retrospective-analysis-of-outcomes-for-primary-mediastinal-large-b-cell-lymphoma-treated-with-rchop-followed-by-radiotherapy-or-front-line-autologous-stem-cell-transplantation
#8
Xiaojian Liu, Ting Deng, Xianzhi Guo, Ye Guo, Leiping Wang, Jian Zhang, Zuguang Xia, Quanling Zhang, Kai Xue, Junning Cao, Jumei Shi, Xiaonan Hong
OBJECTIVES: Our aim was to retrospectively investigate the data from our institute the response rate and outcome in patients with primary mediastinal B-cell lymphoma (PMBL) who received the rituximab in combination with CHOP (RCHOP) followed by autologous stem cell transplantation (ASCT) or RCHOP followed by involved field radiation therapy (IFRT). METHODS: Sixty five patients with PMBL received RCHOP as first-line chemotherapy between January 2005 and December 2010...
November 25, 2016: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27879516/performance-of-a-commercially-available-mal-antibody-in-the-diagnosis-of-primary-mediastinal-large-b-cell-lymphoma
#9
Michael Gentry, Juraj Bodo, Lisa Durkin, Eric D Hsi
Myelin and lymphocyte (MAL) protein has been previously reported as a highly specific marker for distinguishing primary mediastinal large B-cell lymphoma (PMBL) from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). However, there has not been a commercially available MAL antibody for immunohistochemistry. We identified a commercially available MAL monoclonal antibody and evaluated it by immunohistochemistry on 43 cases of PMBL and 63 cases of DLBCL, NOS. We also compared this with a CD200 antibody that was previously reported useful in distinguishing PMBL and DLBCL, NOS...
November 22, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27866679/-hodgkin-and-non-hodgkin-lymphoma-of-adolescents-and-young-adults
#10
REVIEW
Sylvain Garciaz, Diane Coso, Pauline Brice, Réda Bouabdallah
Lymphoma is one of the most frequent cancers in adolescent and young adults. Hodgkin Lymphoma is curable in more than 90% of cases. Recent pediatric and adults protocols aimed to decrease long term toxicities (mostly gonadic and cardiovascular) and secondary malignancies, reducing the use of alkylating agents and limiting radiation fields. Risk-adapted strategies, using positron emission tomography staging, are about to become a standard, both in adult and pediatric protocols. These approaches allow obtaining excellent results in adolescents with Hodgkin lymphoma...
December 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27861596/pd-l1-status-in-refractory-lymphomas
#11
Semir Vranic, Nilanjan Ghosh, Jeffery Kimbrough, Nurija Bilalovic, Ryan Bender, David Arguello, Yvonne Veloso, Aida Dizdarevic, Zoran Gatalica
Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors. A remarkable improvement has also been observed in the treatment of patients with refractory/relapsing classical Hodgkin lymphoma (cHL). We investigated PD-L1 status in a variety of treatment resistant lymphomas. Tumor samples from 78 patients with therapy resistant lymphomas were immunohistochemically (IHC) investigated for the expression of PD-L1 using two antibody clones (SP142 and SP263, Ventana)...
2016: PloS One
https://www.readbyqxmd.com/read/27858330/primary-mediastinal-large-b-cell-lymphoma-in-japanese-children-and-adolescents
#12
Tomoo Osumi, Fumiko Tanaka, Tetsuya Mori, Reiji Fukano, Masahito Tsurusawa, Koichi Oshima, Atsuko Nakazawa, Ryoji Kobayashi
This is the first case series to describe primary mediastinal large B-cell lymphoma (PMLBL) patients in children and adolescents in Asia. We retrospectively identified 17 PMLBL patients diagnosed between 1991 and 2014; in seven of these cases, the diagnosis was confirmed by central review, representing 1.0% of all NHL and 2.2% of all B-NHL cases registered. All patients were teenagers, including seven adolescents, with a median age of 14 years (range 12-18 years). Ten patients were male, and seven were female...
November 17, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27810107/tracheobronchial-obstruction-caused-by-primary-mediastinal-lymphoma
#13
María Luisa Valle Feijoo, Violeta Turcu, Fernando Iglesias Río, Ceferino Gutiérrez Mendiguchia
No abstract text is available yet for this article.
October 31, 2016: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/27806315/primary-mediastinal-large-b-cell-lymphoma-transcriptional-regulation-by-mir-92a-through-foxp1-targeting
#14
Martha Romero, Guillaume Gapihan, Luis Jaime Castro-Vega, Andrés Acevedo, Li Wang, Zhao Wei Li, Morad El Bouchtaoui, Mélanie Di Benedetto, Philippe Ratajczak, Jean-Paul Feugeas, Catherine Thieblemont, Carlos Saavedra, Anne Janin
BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBL) shares pathological features with diffuse large B-cell lymphoma (DLBCL), and molecular features with classical Hodgkin lymphoma (cHL). The miR-17~92 oncogenic cluster, located at chromosome 13q31, is a region that is amplified in DLBCL. METHODS: Here we compared the expression of each member of the miR-17~92 oncogenic cluster in samples from 40 PMBL patients versus 20 DLBCL and 20 cHL patients, and studied the target genes linked to deregulated miRNA in PMBL...
October 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27803409/primary-mediastinal-large-b-cell-lymphoma-exhibiting-endobronchial-involvement
#15
Midori Shimada, Minoru Fukuda, Kensuke Horio, Takayuki Suyama, Takeshi Kitazaki, Kohji Hashiguchi, Masaaki Fukuda, Kazuto Shigematsu, Yoichi Nakamura, Takuya Honda, Kazuto Ashizawa, Hiroshi Mukae
Primary mediastinal large B-cell lymphoma (PMLBCL) is one of the subtypes of diffuse large B-cell lymphoma. We experienced a rare case of PMLBCL that exhibited endobronchial involvement. A 33-year-old Japanese female with the chief complaints of epigastralgia, back pain, and nausea visited a primary care hospital. Computed tomography of the chest and abdomen demonstrated a bulky mass in the left anterior mediastinum, multiple pulmonary nodules, axillary lymph node swelling, and a pancreatic tumor. Fiberoptic bronchoscopy showed a white-tinged irregularly shaped endobronchial tumor accompanied by capillary vessel dilation in the left upper lobar bronchus...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27795778/-primary-mediastinal-large-b-cell-lymphoma-in-women-about-five-cases
#16
Safaa Ouassou, Laila Herrak, Leila Achachi, Fatima Nachite, Kaoutar Znati, Mustapha El Ftouh
Primary mediastinal large B-cell lymphoma (PMBL) is a lymphoma occurring in the anterior mediastinum starting from the cells B of the thymique medullary zone. This is a rare entity characterized by epidemiological, clinical and evolutionary peculiarities as well as by pathological and immunohistochemical peculiarities. We report a case series of 5 patients with diagnosed PMBL hospitalized in Pulmonology Department of Ibn Sina Hospital between January 2012 and May 2016. The average age was 34 years, the median of consultation time was 2 months...
2016: Pan African Medical Journal
https://www.readbyqxmd.com/read/27758822/mediastinal-gray-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-of-99-patients-from-the-lymphoma-study-association
#17
Clémentine Sarkozy, Thierry Molina, Hervé Ghesquières, Anne-Sophie Michallet, Jehan Dupuis, Diane Damotte, Franck Morsschauser, Marie Parrens, Laurent Martin, Peggy Dartigues, Aspasia Stamatoullas, Pierre Hirsch, Bettina Fabiani, Krimo Bouabdallah, Maria Gomes da Silva, Marie Maerevoet, Camille Laurent, Bertrand Coiffier, Gilles Salles, Alexandra Traverse-Glehen
Mediastinal gray zone lymphoma, B-cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma, have not been well described in the literature. We report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis. Cases were defined as classical Hodgkin lymphoma-like morphology (64.6%) with primary mediastinal B-cell lymphoma immunophenotype, primary mediastinal B-cell lymphoma-like morphology (30...
January 2017: Haematologica
https://www.readbyqxmd.com/read/27729935/a-case-of-s-100-negative-melanoma-a-diagnostic-pitfall-in-the-workup-of-a-poorly-differentiated-metastatic-tumor-of-unknown-origin
#18
Anna Biernacka, Konstantinos D Linos, Peter A DeLong, Arief A Suriawinata, Vijayalakshmi Padmanabhan, Xiaoying Liu
When confronted with a metastatic poorly differentiated tumor of unknown origin, the initial workup includes the standard panel of immunostains to rule out carcinoma, sarcoma, lymphoma, and the greatest mimicker in pathology - malignant melanoma. Although not specific, the S-100 protein is expressed in over 95% of malignant melanomas. Herein, we present a case of multiorgan metastatic malignancy with a dominant hilar and mediastinal mass in a current smoker; clinically, highly suggestive of widespread primary lung cancer...
2016: CytoJournal
https://www.readbyqxmd.com/read/27725597/clinical-manifestation-and-treatment-of-extranodal-diffuse-large-b-cell-lymphoma
#19
Naoto Tomita
Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of all lymphoma subtypes. More than half of DLBCLs are estimated to arise from extranodal sites, and are called extranodal DLBCLs. Generally, the outcomes of extranodal DLBCL are not different from those of nodal DLBCL. To our knowledge, this report is the first to discuss the concept and the cell of origin of extranodal DLBCL, with the significance of the presence/absence of each involvement site in determining the outcome. Second, the evidence of clinical manifestation and outcomes of several extranodal DLBCLs requiring treatments other than R-CHOP, which is the current standard therapy for this malignancy, are discussed...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27688726/primary-mediastinal-b-cell-lymphoma-metabolic-and-anatomical-features-in-18fdg-pet-ct-and-response-to-therapy
#20
Anna Kocurek, Bogdan Małkowski, Agnieszka Giza, Wojciech Jurczak
AIM OF THE STUDY: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). MATERIAL AND METHODS: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis)...
2016: Contemporary Oncology Współczesna Onkologia
keyword
keyword
57044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"